DELFI Diagnostics Inc, a developer of next-generation, blood-based tests to help detect cancer, announced on Thursday the appointment of Cindy Soriano as chief financial officer, effective immediately.
Soriano brings 20 years of finance leadership to the role. Prior to joining DELFI, she held senior finance leadership roles across the life sciences sector, including leading the finance organisation at Zogenix through its acquisition by UCB and post-transaction integration. Earlier, Soriano held various leadership roles at BioMarin Pharmaceuticals supporting operational and strategic planning across a diverse portfolio of assets spanning pre-clinical, clinical, and commercial stages.
Susan Tousi, DELFI's CEO, said: "Cindy's promotion comes at a pivotal moment for DELFI as we prepare to achieve key clinical and regulatory milestones. Over the past three and a half years as vice president of Finance and Investor Relations, Cindy has been instrumental in building our financial foundation and guiding us through two successful fundraising rounds. Her strategic vision, operational rigour, and collaborative approach will be essential as we work to deliver on our mission and create long-term value."
Acousia Therapeutics completes patient enrolment in Phase 2 trial of Bimokalner
ZYUS Life Sciences reports positive preliminary results from Phase 2a trial of Trichomylin softgel
Organon signs commercialisation agreement for Nilemdo across six European markets
Antin to acquire clinical trial equipment provider Emsere
Arbele's ARB1002 receives US FDA Orphan Drug Designation
Eli Lilly agrees to acquire Ventyx Biosciences
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
GSK wins European Commission approval for Shingrix prefilled syringe
GSK reports positive phase III results for bepirovirsen in chronic hepatitis B
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Day One completes Mersana acquisition to add rare cancer antibody drug conjugate
Cartography Biosciences partners with Pfizer to discover tumour-selective antigens